Drug-eluting Stents: Cost-Benefit Targeting?

AudioMedica News

Drug-eluting Stents: Cost-Benefit Targeting?

Play Episode Pause Episode

Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds

00:00 /

RSS Feed

Share

Link

Embed

Matthias Pfisterer

Drug-eluting stents and their additional benefit to low-risk patients were investigated in a cost-effectiveness analysis presented to the Stockholm cardiology meeting by Matthias Pfisterer from Basel. Audio Medica talked with him.
[audio:https://www.audiomedica.com/podcasting/14.Matt_Pfisterer-Drug-eluting_stents_may_confer_so_little_additional_benefit_to_low_risk_patients.mp3]

Click here for all the interviews from ESC 2005